Global Preterm Labor Treatment

Preterm Labor Treatment Comprehensive Study by Type (Devices, Cervical Cerclage, Vaginal Pessaries, Drug), Application (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Form (Tablets, Capsules, Injection), Therapy Type (Progesterone, Corticosteroid, Tocolytics, Antibiotics, Heparin Profylaxis, Others) Players and Region - Global Market Outlook to 2026

Preterm Labor Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Preterm Labor Treatment Market?

Preterm labor is when your body starts getting ready for birth too early in your pregnancy. Labor is premature if it starts more than 3 weeks before your due date.A typical pregnancy lasts roughly 40 weeks. Having had a previous premature birth and being pregnant with multiples are two risk factors for premature birth. Immature lungs, trouble regulating body temperature, poor eating, and delayed weight gain are all complications of premature delivery. Premature babies may require additional nursery care, medication, and, in certain cases, surgery. There has been a gradual increase in the number of preterm births in the last few years. The Preterm Birth Prevention and Management includes various therapies which prevent and manage preterm birth. A Preterm Birth Diagnostic Test Kit aids in the detection of preterm labor and the possibility of premature membrane rupture. The increased emphasis on cost-effective diagnosis for detecting preterm birth is attributed to the market growth

The market study is being classified by Type (Devices, Cervical Cerclage, Vaginal Pessaries and Drug), by Application (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes and Pharmacy) and major geographies with country level break-up.

AbbVie Inc. (United States), Allergan (Ireland), AMAG Pharmaceuticals (United States), Bayer AG (Germany), Ferring B.V. (Switzerland), Merck & Co. Inc. (United States), Mylan N.V. (United States), Pfizer Inc. (United States), CooperSurgical, Inc. (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are IQ Products (Netherlands), Medgyn Products (United States), Anhui Deep Blue Medical Technology (China) and Nanjing Liming Biological Preparations Co Ltd (China).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Preterm Labor Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Preterm Labor Treatment market by Type, Application and Region.

On the basis of geography, the market of Preterm Labor Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Need for Preterm Birth Prevention and Management Drugs
  • Growing Demand for Cost Effective Diagnosis of Preterm Births
  • Growing Focus on Targeted Therapies and Standard of Care

Market Trend
  • Rapid Preterm Birth Diagnostic Test Kits

Restraints
  • Adverse Effects Associated with Medication
  • Lack of Awareness about Treatment

Opportunities
  • Promotional Activities to Increase Awareness
  • Growth Opportunities in Untapped Markets in the Developing Countries

Challenges
  • Stringent Regulatory Factors for Drugs and Devices


May 2020 – U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) proposed that Makena (hydroxyprogesterone caproate injection) be withdrawn from the market because the required postmarket study failed to verify clinical benefit and we have concluded that the available evidence does not show Makena is effective for its approved use.
Preterm Labor Treatment devices require the FDA Pre Market Approval. The applicant must receive FDA approval of its PMA application prior to marketing the device. PMA approval is based on a determination by FDA that the PMA contains sufficient valid scientific evidence to assure that the device is safe and effective for its intended use

Key Target Audience
Pharmaceutical Companies, Healthcare Industry, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Devices
  • Cervical Cerclage
  • Vaginal Pessaries
  • Drug
By Application
  • Hospitals
  • Pediatric and Neonatal Clinics
  • Nursing Homes
  • Pharmacy
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Form
  • Tablets
  • Capsules
  • Injection

By Therapy Type
  • Progesterone
  • Corticosteroid
  • Tocolytics
  • Antibiotics
  • Heparin Profylaxis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Need for Preterm Birth Prevention and Management Drugs
      • 3.2.2. Growing Demand for Cost Effective Diagnosis of Preterm Births
      • 3.2.3. Growing Focus on Targeted Therapies and Standard of Care
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors for Drugs and Devices
    • 3.4. Market Trends
      • 3.4.1. Rapid Preterm Birth Diagnostic Test Kits
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Preterm Labor Treatment, by Type, Application, Distribution Channel, Form, Therapy Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Preterm Labor Treatment (Value)
      • 5.2.1. Global Preterm Labor Treatment by: Type (Value)
        • 5.2.1.1. Devices
        • 5.2.1.2. Cervical Cerclage
        • 5.2.1.3. Vaginal Pessaries
        • 5.2.1.4. Drug
      • 5.2.2. Global Preterm Labor Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pediatric and Neonatal Clinics
        • 5.2.2.3. Nursing Homes
        • 5.2.2.4. Pharmacy
      • 5.2.3. Global Preterm Labor Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Preterm Labor Treatment by: Form (Value)
        • 5.2.4.1. Tablets
        • 5.2.4.2. Capsules
        • 5.2.4.3. Injection
      • 5.2.5. Global Preterm Labor Treatment by: Therapy Type (Value)
        • 5.2.5.1. Progesterone
        • 5.2.5.2. Corticosteroid
        • 5.2.5.3. Tocolytics
        • 5.2.5.4. Antibiotics
        • 5.2.5.5. Heparin Profylaxis
        • 5.2.5.6. Others
      • 5.2.6. Global Preterm Labor Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Preterm Labor Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AMAG Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ferring B.V. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CooperSurgical, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Preterm Labor Treatment Sale, by Type, Application, Distribution Channel, Form, Therapy Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Preterm Labor Treatment (Value)
      • 7.2.1. Global Preterm Labor Treatment by: Type (Value)
        • 7.2.1.1. Devices
        • 7.2.1.2. Cervical Cerclage
        • 7.2.1.3. Vaginal Pessaries
        • 7.2.1.4. Drug
      • 7.2.2. Global Preterm Labor Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pediatric and Neonatal Clinics
        • 7.2.2.3. Nursing Homes
        • 7.2.2.4. Pharmacy
      • 7.2.3. Global Preterm Labor Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Preterm Labor Treatment by: Form (Value)
        • 7.2.4.1. Tablets
        • 7.2.4.2. Capsules
        • 7.2.4.3. Injection
      • 7.2.5. Global Preterm Labor Treatment by: Therapy Type (Value)
        • 7.2.5.1. Progesterone
        • 7.2.5.2. Corticosteroid
        • 7.2.5.3. Tocolytics
        • 7.2.5.4. Antibiotics
        • 7.2.5.5. Heparin Profylaxis
        • 7.2.5.6. Others
      • 7.2.6. Global Preterm Labor Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Preterm Labor Treatment: by Type(USD Million)
  • Table 2. Preterm Labor Treatment Devices , by Region USD Million (2015-2020)
  • Table 3. Preterm Labor Treatment Cervical Cerclage , by Region USD Million (2015-2020)
  • Table 4. Preterm Labor Treatment Vaginal Pessaries , by Region USD Million (2015-2020)
  • Table 5. Preterm Labor Treatment Drug , by Region USD Million (2015-2020)
  • Table 6. Preterm Labor Treatment: by Application(USD Million)
  • Table 7. Preterm Labor Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Preterm Labor Treatment Pediatric and Neonatal Clinics , by Region USD Million (2015-2020)
  • Table 9. Preterm Labor Treatment Nursing Homes , by Region USD Million (2015-2020)
  • Table 10. Preterm Labor Treatment Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Preterm Labor Treatment: by Distribution Channel(USD Million)
  • Table 12. Preterm Labor Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Preterm Labor Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Preterm Labor Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Preterm Labor Treatment Others , by Region USD Million (2015-2020)
  • Table 16. Preterm Labor Treatment: by Form(USD Million)
  • Table 17. Preterm Labor Treatment Tablets , by Region USD Million (2015-2020)
  • Table 18. Preterm Labor Treatment Capsules , by Region USD Million (2015-2020)
  • Table 19. Preterm Labor Treatment Injection , by Region USD Million (2015-2020)
  • Table 20. Preterm Labor Treatment: by Therapy Type(USD Million)
  • Table 21. Preterm Labor Treatment Progesterone , by Region USD Million (2015-2020)
  • Table 22. Preterm Labor Treatment Corticosteroid , by Region USD Million (2015-2020)
  • Table 23. Preterm Labor Treatment Tocolytics , by Region USD Million (2015-2020)
  • Table 24. Preterm Labor Treatment Antibiotics , by Region USD Million (2015-2020)
  • Table 25. Preterm Labor Treatment Heparin Profylaxis , by Region USD Million (2015-2020)
  • Table 26. Preterm Labor Treatment Others , by Region USD Million (2015-2020)
  • Table 27. South America Preterm Labor Treatment, by Country USD Million (2015-2020)
  • Table 28. South America Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 29. South America Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 30. South America Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. South America Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 32. South America Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 33. Brazil Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 34. Brazil Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 35. Brazil Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. Brazil Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 37. Brazil Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 38. Argentina Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 39. Argentina Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 40. Argentina Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. Argentina Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 42. Argentina Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 43. Rest of South America Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 44. Rest of South America Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 45. Rest of South America Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 46. Rest of South America Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 47. Rest of South America Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 48. Asia Pacific Preterm Labor Treatment, by Country USD Million (2015-2020)
  • Table 49. Asia Pacific Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 50. Asia Pacific Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 51. Asia Pacific Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Asia Pacific Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 53. Asia Pacific Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 54. China Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 55. China Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 56. China Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. China Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 58. China Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 59. Japan Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 60. Japan Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 61. Japan Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. Japan Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 63. Japan Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 64. India Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 65. India Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 66. India Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. India Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 68. India Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 69. South Korea Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 70. South Korea Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 71. South Korea Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. South Korea Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 73. South Korea Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 74. Taiwan Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 75. Taiwan Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 76. Taiwan Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 77. Taiwan Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 78. Taiwan Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 79. Australia Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 80. Australia Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 81. Australia Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. Australia Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 83. Australia Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 87. Rest of Asia-Pacific Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 88. Rest of Asia-Pacific Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 89. Europe Preterm Labor Treatment, by Country USD Million (2015-2020)
  • Table 90. Europe Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 91. Europe Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 92. Europe Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 93. Europe Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 94. Europe Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 95. Germany Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 96. Germany Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 97. Germany Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 98. Germany Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 99. Germany Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 100. France Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 101. France Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 102. France Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 103. France Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 104. France Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 105. Italy Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 106. Italy Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 107. Italy Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 108. Italy Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 109. Italy Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 110. United Kingdom Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 111. United Kingdom Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 112. United Kingdom Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 113. United Kingdom Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 114. United Kingdom Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 115. Netherlands Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 116. Netherlands Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 117. Netherlands Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 118. Netherlands Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 119. Netherlands Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 120. Rest of Europe Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 121. Rest of Europe Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 122. Rest of Europe Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 123. Rest of Europe Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 124. Rest of Europe Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 125. MEA Preterm Labor Treatment, by Country USD Million (2015-2020)
  • Table 126. MEA Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 127. MEA Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 128. MEA Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 129. MEA Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 130. MEA Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 131. Middle East Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 132. Middle East Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 133. Middle East Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 134. Middle East Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 135. Middle East Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 136. Africa Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 137. Africa Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 138. Africa Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 139. Africa Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 140. Africa Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 141. North America Preterm Labor Treatment, by Country USD Million (2015-2020)
  • Table 142. North America Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 143. North America Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 144. North America Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 145. North America Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 146. North America Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 147. United States Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 148. United States Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 149. United States Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 150. United States Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 151. United States Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 152. Canada Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 153. Canada Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 154. Canada Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 155. Canada Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 156. Canada Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 157. Mexico Preterm Labor Treatment, by Type USD Million (2015-2020)
  • Table 158. Mexico Preterm Labor Treatment, by Application USD Million (2015-2020)
  • Table 159. Mexico Preterm Labor Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 160. Mexico Preterm Labor Treatment, by Form USD Million (2015-2020)
  • Table 161. Mexico Preterm Labor Treatment, by Therapy Type USD Million (2015-2020)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Preterm Labor Treatment: by Type(USD Million)
  • Table 173. Preterm Labor Treatment Devices , by Region USD Million (2021-2026)
  • Table 174. Preterm Labor Treatment Cervical Cerclage , by Region USD Million (2021-2026)
  • Table 175. Preterm Labor Treatment Vaginal Pessaries , by Region USD Million (2021-2026)
  • Table 176. Preterm Labor Treatment Drug , by Region USD Million (2021-2026)
  • Table 177. Preterm Labor Treatment: by Application(USD Million)
  • Table 178. Preterm Labor Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 179. Preterm Labor Treatment Pediatric and Neonatal Clinics , by Region USD Million (2021-2026)
  • Table 180. Preterm Labor Treatment Nursing Homes , by Region USD Million (2021-2026)
  • Table 181. Preterm Labor Treatment Pharmacy , by Region USD Million (2021-2026)
  • Table 182. Preterm Labor Treatment: by Distribution Channel(USD Million)
  • Table 183. Preterm Labor Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 184. Preterm Labor Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 185. Preterm Labor Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 186. Preterm Labor Treatment Others , by Region USD Million (2021-2026)
  • Table 187. Preterm Labor Treatment: by Form(USD Million)
  • Table 188. Preterm Labor Treatment Tablets , by Region USD Million (2021-2026)
  • Table 189. Preterm Labor Treatment Capsules , by Region USD Million (2021-2026)
  • Table 190. Preterm Labor Treatment Injection , by Region USD Million (2021-2026)
  • Table 191. Preterm Labor Treatment: by Therapy Type(USD Million)
  • Table 192. Preterm Labor Treatment Progesterone , by Region USD Million (2021-2026)
  • Table 193. Preterm Labor Treatment Corticosteroid , by Region USD Million (2021-2026)
  • Table 194. Preterm Labor Treatment Tocolytics , by Region USD Million (2021-2026)
  • Table 195. Preterm Labor Treatment Antibiotics , by Region USD Million (2021-2026)
  • Table 196. Preterm Labor Treatment Heparin Profylaxis , by Region USD Million (2021-2026)
  • Table 197. Preterm Labor Treatment Others , by Region USD Million (2021-2026)
  • Table 198. South America Preterm Labor Treatment, by Country USD Million (2021-2026)
  • Table 199. South America Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 200. South America Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 201. South America Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 202. South America Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 203. South America Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 204. Brazil Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 205. Brazil Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 206. Brazil Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 207. Brazil Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 208. Brazil Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 209. Argentina Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 210. Argentina Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 211. Argentina Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 212. Argentina Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 213. Argentina Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 214. Rest of South America Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 215. Rest of South America Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 216. Rest of South America Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 217. Rest of South America Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 218. Rest of South America Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 219. Asia Pacific Preterm Labor Treatment, by Country USD Million (2021-2026)
  • Table 220. Asia Pacific Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 221. Asia Pacific Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 222. Asia Pacific Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 223. Asia Pacific Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 224. Asia Pacific Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 225. China Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 226. China Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 227. China Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 228. China Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 229. China Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 230. Japan Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 231. Japan Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 232. Japan Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 233. Japan Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 234. Japan Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 235. India Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 236. India Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 237. India Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 238. India Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 239. India Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 240. South Korea Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 241. South Korea Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 242. South Korea Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 243. South Korea Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 244. South Korea Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 245. Taiwan Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 246. Taiwan Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 247. Taiwan Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 248. Taiwan Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 249. Taiwan Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 250. Australia Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 251. Australia Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 252. Australia Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 253. Australia Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 254. Australia Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 256. Rest of Asia-Pacific Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 257. Rest of Asia-Pacific Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 258. Rest of Asia-Pacific Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 259. Rest of Asia-Pacific Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 260. Europe Preterm Labor Treatment, by Country USD Million (2021-2026)
  • Table 261. Europe Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 262. Europe Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 263. Europe Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 264. Europe Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 265. Europe Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 266. Germany Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 267. Germany Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 268. Germany Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 269. Germany Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 270. Germany Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 271. France Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 272. France Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 273. France Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 274. France Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 275. France Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 276. Italy Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 277. Italy Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 278. Italy Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 279. Italy Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 280. Italy Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 281. United Kingdom Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 282. United Kingdom Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 283. United Kingdom Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 284. United Kingdom Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 285. United Kingdom Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 286. Netherlands Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 287. Netherlands Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 288. Netherlands Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 289. Netherlands Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 290. Netherlands Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 291. Rest of Europe Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 292. Rest of Europe Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 293. Rest of Europe Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 294. Rest of Europe Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 295. Rest of Europe Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 296. MEA Preterm Labor Treatment, by Country USD Million (2021-2026)
  • Table 297. MEA Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 298. MEA Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 299. MEA Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 300. MEA Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 301. MEA Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 302. Middle East Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 303. Middle East Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 304. Middle East Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 305. Middle East Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 306. Middle East Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 307. Africa Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 308. Africa Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 309. Africa Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 310. Africa Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 311. Africa Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 312. North America Preterm Labor Treatment, by Country USD Million (2021-2026)
  • Table 313. North America Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 314. North America Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 315. North America Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 316. North America Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 317. North America Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 318. United States Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 319. United States Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 320. United States Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 321. United States Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 322. United States Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 323. Canada Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 324. Canada Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 325. Canada Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 326. Canada Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 327. Canada Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 328. Mexico Preterm Labor Treatment, by Type USD Million (2021-2026)
  • Table 329. Mexico Preterm Labor Treatment, by Application USD Million (2021-2026)
  • Table 330. Mexico Preterm Labor Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 331. Mexico Preterm Labor Treatment, by Form USD Million (2021-2026)
  • Table 332. Mexico Preterm Labor Treatment, by Therapy Type USD Million (2021-2026)
  • Table 333. Research Programs/Design for This Report
  • Table 334. Key Data Information from Secondary Sources
  • Table 335. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Preterm Labor Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Preterm Labor Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Preterm Labor Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Preterm Labor Treatment: by Form USD Million (2015-2020)
  • Figure 8. Global Preterm Labor Treatment: by Therapy Type USD Million (2015-2020)
  • Figure 9. South America Preterm Labor Treatment Share (%), by Country
  • Figure 10. Asia Pacific Preterm Labor Treatment Share (%), by Country
  • Figure 11. Europe Preterm Labor Treatment Share (%), by Country
  • Figure 12. MEA Preterm Labor Treatment Share (%), by Country
  • Figure 13. North America Preterm Labor Treatment Share (%), by Country
  • Figure 14. Global Preterm Labor Treatment share by Players 2020 (%)
  • Figure 15. Global Preterm Labor Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Preterm Labor Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 22. AMAG Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 23. AMAG Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 26. Ferring B.V. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Ferring B.V. (Switzerland) Revenue: by Geography 2020
  • Figure 28. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 34. CooperSurgical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. CooperSurgical, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 37. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 38. Global Preterm Labor Treatment: by Type USD Million (2021-2026)
  • Figure 39. Global Preterm Labor Treatment: by Application USD Million (2021-2026)
  • Figure 40. Global Preterm Labor Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 41. Global Preterm Labor Treatment: by Form USD Million (2021-2026)
  • Figure 42. Global Preterm Labor Treatment: by Therapy Type USD Million (2021-2026)
  • Figure 43. South America Preterm Labor Treatment Share (%), by Country
  • Figure 44. Asia Pacific Preterm Labor Treatment Share (%), by Country
  • Figure 45. Europe Preterm Labor Treatment Share (%), by Country
  • Figure 46. MEA Preterm Labor Treatment Share (%), by Country
  • Figure 47. North America Preterm Labor Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Allergan (Ireland)
  • AMAG Pharmaceuticals (United States)
  • Bayer AG (Germany)
  • Ferring B.V. (Switzerland)
  • Merck & Co. Inc. (United States)
  • Mylan N.V. (United States)
  • Pfizer Inc. (United States)
  • CooperSurgical, Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Additional players considered in the study are as follows:
IQ Products (Netherlands) , Medgyn Products (United States) , Anhui Deep Blue Medical Technology (China) , Nanjing Liming Biological Preparations Co Ltd (China)
Select User Access Type

Key Highlights of Report


May 2021 248 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Preterm Labor Treatment Quantitative research analysis
Global Preterm Labor Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Need for Preterm Birth Prevention and Management Drugs " is seen as one of major growth factors of Preterm Labor Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Preterm Labor Treatment Report?

Have a Query? Click Here

Other Related Reports

Parkinson's Disease Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics), Drug Class (Carbido...
$ 3650
Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Admin...
$ 3650
Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), En...
$ 3450
Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
$ 3750
Hodgkin Lymphoma Treatment Comprehensive Study by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), Application (Hospital, Clinic, Research Center), Treatment (Immunotherapy, Ra...
$ 3650
Cervical Cancer Diagnostic Tests Comprehensive Study by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy, Bimanual Pelvic Examination), Application (Hospitals, Specialty Clinics, Cancer and Radiat...
$ 3450